TRAVIS BAIRD: Open Payments
NPI 1235548314 · GLEN BURNIE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,786 in 179 payments from 23 companies in 2025. Trend: 2023 $1,047 · 2024 $2,015 · 2025 $4,786
Food & beverage: $4,153Travel & lodging: $624Education: $9
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 10 | $860 |
| ABBVIE INC. | 28 | $418 |
| Alkermes, Inc. | 20 | $392 |
| E.R. Squibb & Sons, L.L.C. | 12 | $364 |
| Neurocrine BioSciences, Inc. | 8 | $347 |
| Teva Pharmaceuticals USA, Inc. | 14 | $267 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $263 |
| Gilead Sciences, Inc. | 5 | $260 |
| Lundbeck LLC | 14 | $223 |
| Otsuka America Pharmaceutical, Inc. | 6 | $222 |
Products named: SPRAVATO, VRAYLAR, COBENFY, INGREZZA, REXULTI, CAPLYTA, Epclusa, Qelbree.
Industry payments across MD — which companies pay providers there.
